论文部分内容阅读
美国华盛顿消息:据在美国正进行的放射性标记单克隆抗体试验的一家公司称,在测定心脏病发作引起的坏死性损伤方面,放射性标记的单克隆抗体非常有效。宾夕法尼亚莫尔文Centocor公司生产了111铟标记的抗肌凝蛋白单克隆抗体,目前投放到意大利澳大利亚和荷兰市场。Centocor公司医学事务部第一副主任Harvey Berger在最近核医学协会(SNM)年会上报告了美国4个
Washington, DC, USA: According to a company that is conducting a radioactively labeled monoclonal antibody test in the United States, radiolabeled monoclonal antibodies are very effective in determining the necrotic damage caused by a heart attack. Centocor, PA produces 111 indium-labeled anti-myosin monoclonal antibody and is currently shipping to the Italian market in Australia and the Netherlands. Harvey Berger, First Deputy Director of Centocor’s Medical Affairs Division, reported at the recent annual meeting of the Nuclear Medicine Association (SNM) that four